Sarcoma Drugs Market Size, Share & Industry Analysis, By Drug (Imatinib, Pazopanib, Ripretinib, Nirogacestat, Trabectedin, Avapritinib, & Others), By Drug Class (Cytotoxic Chemotherapy, Tyrosine Kinase Inhibitors, Gamma Secretase Inhibitors, Immune Checkpoint Inhibitors, EZH2 Inhibitors), By Disease Indication (GIST, Leiomyosarcoma, Liposarcoma, Desmoid Tumors), By Age Group (Pediatric and Adults), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), By Route of Administration, By Distribution Channel (Hospital Pharmacies, Retail/Online Pharmacies), and Regional Forecast, 2026-2034

Last Updated: April 26, 2026 | Format: PDF | Report ID: FBI116010

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 8.41% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Region
By Drug	Imatinib Pazopanib Ripretinib Nirogacestat Trabectedin Avapritinib Others
By Drug Class	Cytotoxic Chemotherapy Tyrosine Kinase Inhibitors (TKIs) Gamma Secretase Inhibitors Immune Checkpoint Inhibitors Cell Therapies Epigenetic/EZH2 Inhibitors Others
By Disease Indication	Gastrointestinal Stromal Tumor (GIST) Leiomyosarcoma Liposarcoma Synovial Sarcoma Desmoid Tumors Osteosarcoma Others
By Age Group	Pediatric Adults
By Type	Branded Generic
By Therapy	Targeted Therapy Immunotherapy Chemotherapy Others
By Route of Administration	Oral Parenteral
By Distribution Channel	Hospital Pharmacies Drug stores & retail pharmacies Online Pharmacies
By Region	North America (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa